- Home
- HTGC vs BHVN Comparison
HTGC vs BHVN Comparison
Compare HTGC & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- BHVN
- Stock Information
- Founded
- HTGC 2003
- BHVN 2013
- Country
- HTGC United States
- BHVN United States
- Employees
- HTGC N/A
- BHVN N/A
- Industry
- HTGC Investment Managers
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- HTGC Finance
- BHVN Health Care
- Exchange
- HTGC Nasdaq
- BHVN Nasdaq
- Market Cap
- HTGC 3.5B
- BHVN 1.5B
- IPO Year
- HTGC 2005
- BHVN 2017
- Fundamental
- Price
- HTGC $19.32
- BHVN $15.61
- Analyst Decision
- HTGC Buy
- BHVN Strong Buy
- Analyst Count
- HTGC 8
- BHVN 16
- Target Price
- HTGC $21.31
- BHVN $52.13
- AVG Volume (30 Days)
- HTGC 770.5K
- BHVN 2.0M
- Earning Date
- HTGC 10-29-2025
- BHVN 11-11-2025
- Dividend Yield
- HTGC 9.80%
- BHVN N/A
- EPS Growth
- HTGC N/A
- BHVN N/A
- EPS
- HTGC 1.52
- BHVN N/A
- Revenue
- HTGC $504,002,000.00
- BHVN N/A
- Revenue This Year
- HTGC $8.25
- BHVN N/A
- Revenue Next Year
- HTGC $7.47
- BHVN $2,195.07
- P/E Ratio
- HTGC $12.65
- BHVN N/A
- Revenue Growth
- HTGC 3.72
- BHVN N/A
- 52 Week Low
- HTGC $15.65
- BHVN $12.79
- 52 Week High
- HTGC $22.04
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- HTGC 51.70
- BHVN 56.51
- Support Level
- HTGC $19.07
- BHVN $13.41
- Resistance Level
- HTGC $19.39
- BHVN $14.23
- Average True Range (ATR)
- HTGC 0.22
- BHVN 0.87
- MACD
- HTGC -0.03
- BHVN -0.05
- Stochastic Oscillator
- HTGC 45.45
- BHVN 57.03
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.